Medical, Scientific, and Regulatory Updates
MIKS curates reliable and high-quality information published in the field of regenerative medicine, ensuring you can effortlessly stay current.
Certain news pieces are exclusively available to members. If you wish for unrestricted access to all news articles, you can achieve that by becoming a member of our community. Join as a member today to enjoy complete access to all our content.
04 julio 2024
SCIENTIFIC HIGHLIGHTS
Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios
The ESSKA-ICRS consensus developed evidence-based and expert recommendations on the appropriateness of intra-articular platelet-rich plasma (PRP) injections for different clinical scenarios in patients with knee osteoarthritis, using the RAND/UCLA appropriateness method. Scenarios were defined according to initial treatment, age, tibiofemoral or patellofemoral involvement, level of osteoarthritis (Kellgren-Lawrence) and presence of joint effusion. Of 216 scenarios, 38.9% were considered appropriate, 4.2% inappropriate and 56.9% uncertain. The highest consensuses were for the use of PRP after failed injective treatments (62.5%) and failed conservative treatments in osteoarthritis KL 0-III (58.3%). The highest uncertainty was for PRP as first treatment and in KL IV osteoarthritis (91.7% and 87.5% uncertainty, respectively). This ESSKA-ICRS consensus establishes recommendations on the appropriateness or inappropriateness of PRP injections for the treatment of knee OA, providing a useful reference for clinical practice. PRP injections are appropriate in patients ≤80 years with KL 0-III osteoarthritis after failed conservative treatments, but not as first treatment or in KL IV osteoarthritis.
You can access the study HERE
Image gallery